Back to News
Market Impact: 0.2
HUTCHMED (China) Limited Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA granted Orphan Drug Designation to HUTCHMED’s sovleplenib for treatment of primary immune thrombocytopenia, an autoimmune disorder that can increase bleeding risk. The designation is a development milestone; it is not an approval of the drug for marketing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
HCM0.45
More News
- Analysts react as Binance freezes assets after $6.3 billion security breach
- Spanish PM, facing reelection, says it’s ‘unacceptable’ to suffer two high-speed rail accidents in one year as at least 68 die in collision
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- US plans to ban Chinese telecom firms from direct access to US phone numbers
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside